Bayesian selective response‐adaptive design using the historical control

High quality historical control data, if incorporated, may reduce sample size, trial cost, and duration. A too optimistic use of the data, however, may result in bias under prior‐data conflict. Motivated by well‐publicized two‐arm comparative trials in stroke, we propose a Bayesian design that both adaptively incorporates historical control data and selectively adapt the treatment allocation ratios within an ongoing trial responsively to the relative treatment effects. The proposed design differs from existing designs that borrow from historical controls. As opposed to reducing the number of subjects assigned to the control arm blindly, this design does so adaptively to the relative treatment effects only if evaluation of cumulated current trial data combined with the historical control suggests the superiority of the intervention arm. We used the effective historical sample size approach to quantify borrowed information on the control arm and modified the treatment allocation rules of the doubly adaptive biased coin design to incorporate the quantity. The modified allocation rules were then implemented under the Bayesian framework with commensurate priors addressing prior‐data conflict. Trials were also more frequently concluded earlier in line with the underlying truth, reducing trial cost, and duration and yielded parameter estimates with smaller standard errors.

[1]  Daron Acemoglu,et al.  Discussion Papers , 2007 .

[2]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[3]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[4]  A. Dempster,et al.  Combining Historical and Randomized Controls for Assessing Trends in Proportions , 1983 .

[5]  R. Peto Discussion of 'On the Allocation of Treatments in Sequential Medical Trials' by J.A. Bather and 'The Search for Optimality in Clinical Trials' by P. Armitage , 1985 .

[6]  T. J. Mitchell,et al.  Bayesian Variable Selection in Linear Regression , 1988 .

[7]  L Ryan,et al.  Using historical controls in the analysis of developmental toxicity data. , 1993, Biometrics.

[8]  D. Berry,et al.  Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.

[9]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[10]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[11]  J. Grotta,et al.  Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. , 1999, Stroke.

[12]  William F. Rosenberger,et al.  Optimality, Variability, Power , 2003 .

[13]  D. Spiegelhalter,et al.  Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .

[14]  Ims Study Investigators Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study , 2004, Stroke.

[15]  Feifang Hu,et al.  Maximizing power and minimizing treatment failures in clinical trials , 2004, Clinical trials.

[16]  W. Rosenberger,et al.  The theory of response-adaptive randomization in clinical trials , 2006 .

[17]  C. Assaid,et al.  The Theory of Response-Adaptive Randomization in Clinical Trials , 2007 .

[18]  Ims Ii Trial Investigators,et al.  The Interventional Management of Stroke (IMS) II Study , 2007 .

[19]  Joseph P. Broderick,et al.  Methodology of the Interventional Management of Stroke III Trial , 2008, International journal of stroke : official journal of the International Stroke Society.

[20]  Feifang Hu,et al.  Doubly adaptive biased coin designs with delayed responses , 2008 .

[21]  Jing Ning,et al.  Using short‐term response information to facilitate adaptive randomization for survival clinical trials , 2009, Statistics in medicine.

[22]  Bradley P Carlin,et al.  Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.

[23]  B. Freidlin,et al.  Outcome--adaptive randomization: is it useful? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Joseph G Ibrahim,et al.  Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes , 2012, Biometrics.

[25]  Bradley P Carlin,et al.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.

[26]  G. Yin,et al.  Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization , 2012, Clinical Cancer Research.

[27]  Brian P Hobbs,et al.  Adaptive adjustment of the randomization ratio using historical control data , 2013, Clinical trials.

[28]  Joseph G Ibrahim,et al.  Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome. , 2014, Biometrics.

[29]  Mi-Ok Kim,et al.  Outcome‐adaptive randomization for a delayed outcome with a short‐term predictor: imputation‐based designs , 2014, Statistics in medicine.

[30]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[31]  Joseph G Ibrahim,et al.  Bayesian sequential meta‐analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program , 2014, Statistics in medicine.

[32]  J. Kimmelman,et al.  Are outcome-adaptive allocation trials ethical? , 2015, Clinical trials.

[33]  G. Yule On the Methods of Measuring Association between Two Attributes , 1912 .